NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sang-Heon | - |
dc.contributor.author | Kim, Sang-Hoon | - |
dc.contributor.author | Yoon, Ho Joo | - |
dc.contributor.author | Shin, Dong Ho | - |
dc.contributor.author | Park, Sung Soo | - |
dc.contributor.author | Kim, Youn-Seup | - |
dc.contributor.author | Park, Jae-Seuk | - |
dc.contributor.author | Jee, Young Koo | - |
dc.date.accessioned | 2022-07-16T21:51:38Z | - |
dc.date.available | 2022-07-16T21:51:38Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2011-02 | - |
dc.identifier.issn | 0031-6970 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/169119 | - |
dc.description.abstract | Purpose It has been suggested that drug-metabolizing enzymes might play important roles in the development of anti-tuberculosis drug (ATD)-induced maculopapular eruption (MPE), as in ATD-induced hepatitis. We investigated the associations between the genetic polymorphisms of drug-metabolizing enzymes and ATD-induced MPE. Methods We enrolled 62 patients with ATD-induced MPE (mean age 47.2 +/- 19.0, male 59.7%) and 159 patients without any adverse reactions to ATD (mean age 42.8 +/- 17.6, male 65.4%), among patients with pulmonary tuberculosis (TB) and/or TB pleuritis and treated with first-line anti-TB medications, including isoniazid, rifampin, ethambutol, and pyrazinamide. We compared the genotype distributions of single nucleotide polymorphisms and haplotypes in four drug-metabolizing enzymes (N-acetyltransferase 2 (NAT2), cytochrome P450 (CYP) 2 C9, CYP2C19, and CYP2E1) among patients with ATD-induced MPE and patients tolerant to ATD using a multivariate logistic regression analysis. These analyses were made without identification of the responsible ATD. Results -1565 C>T of CYP2C9 showed a significant association with ATD-induced MPE (P=0.022, OR=0.23, 95% CI 0.07-0.78), with a lower frequency of genotypes carrying minor alleles (CT or TT) in the case group than in the controls. Additionally, W212X of CYP2C19 was significantly associated with the risk of ATD-induced MPE (P=0.042, OR=0.27, 95% CI 0.09-0.82). In an analysis of the CYP2C19 CYP2C9 haplotypes (-1418 C> T_W212X_-1565 C>T_-1188 C>T), ht3[T-A-T-C] showed a significant association with the development of ATD-induced MPE (P=0.012, OR=0.13, 95% CI 0.03-0.57). No significant associations between the other genetic polymorphisms and ATD-induced MPE were observed. Conclusions CYP2C19 and CYP2C9 genetic polymorphisms are significantly associated with the risk of developing ATD-induced MPE, and the genetic variants in NAT2 and CYP2E1 are not closely related to the development of this adverse reaction. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.title | NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sang-Heon | - |
dc.contributor.affiliatedAuthor | Yoon, Ho Joo | - |
dc.identifier.doi | 10.1007/s00228-010-0912-4 | - |
dc.identifier.scopusid | 2-s2.0-79151483041 | - |
dc.identifier.wosid | 000286783900002 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.67, no.2, pp.121 - 127 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.title | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.volume | 67 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 121 | - |
dc.citation.endPage | 127 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | 1ST-LINE ANTITUBERCULOSIS DRUGS | - |
dc.subject.keywordPlus | S-TRANSFERASE M1 | - |
dc.subject.keywordPlus | INDUCED HEPATOTOXICITY | - |
dc.subject.keywordPlus | INDUCED HEPATITIS | - |
dc.subject.keywordPlus | ADVERSE-REACTIONS | - |
dc.subject.keywordPlus | NULL MUTATIONS | - |
dc.subject.keywordPlus | SUSCEPTIBILITY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | TUBERCULOSIS | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordAuthor | Anti-TB drugs | - |
dc.subject.keywordAuthor | Maculopapular eruption | - |
dc.subject.keywordAuthor | Drug-metabolizing enzymes | - |
dc.subject.keywordAuthor | Polymorphism | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00228-010-0912-4 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.